Abstract
Interest for extracellular nucleotides has increased since the pioneer work of Burnstock in the early seventies. Research on cellular functions modulated by purines and pyrimidines has led to the identification and characterization of the different components of purine signaling, namely purinoceptors and ecto-nucleotidases. Receptors for tri- and diphosphonucleosides, known as P2 nucleotide receptors, are designated either P2Y receptors, for those coupled to Gproteins, or P2X for those which are ligand gated-ion channels. Ecto-nucleoside triphosphate diphosphohydrolase (NTPDase; EC 3.6.1.5), previously identified as ecto-ATPase, ecto-ATPDase or CD39, is now considered as the main ecto-nucleotidase responsible for the sequential hydrolysis of beta and gamma phosphates of tri- and diphosphonucleosides. More recently, research has been focused on the development of specific agonists and antagonists to P2 purinoceptors. The need to develop specific inhibitors for NTPDase to understand the role of this enzyme has clearly emerged. This paper covers the development of specific molecules targeting purinergic signaling, more specifically the inhibition of NTPDase and their impact on the different physiological systems.
Current Drug Targets
Title: Purine Signaling and Potential New Therapeutic Approach: Possible Outcomes of NTPDase Inhibition
Volume: 3 Issue: 3
Author(s): F.P. Gendron, O. Benrezzak, B.W. Krugh, Q. Kong, G.A. Weisman and A.R. Beaudoin
Affiliation:
Abstract: Interest for extracellular nucleotides has increased since the pioneer work of Burnstock in the early seventies. Research on cellular functions modulated by purines and pyrimidines has led to the identification and characterization of the different components of purine signaling, namely purinoceptors and ecto-nucleotidases. Receptors for tri- and diphosphonucleosides, known as P2 nucleotide receptors, are designated either P2Y receptors, for those coupled to Gproteins, or P2X for those which are ligand gated-ion channels. Ecto-nucleoside triphosphate diphosphohydrolase (NTPDase; EC 3.6.1.5), previously identified as ecto-ATPase, ecto-ATPDase or CD39, is now considered as the main ecto-nucleotidase responsible for the sequential hydrolysis of beta and gamma phosphates of tri- and diphosphonucleosides. More recently, research has been focused on the development of specific agonists and antagonists to P2 purinoceptors. The need to develop specific inhibitors for NTPDase to understand the role of this enzyme has clearly emerged. This paper covers the development of specific molecules targeting purinergic signaling, more specifically the inhibition of NTPDase and their impact on the different physiological systems.
Export Options
About this article
Cite this article as:
F.P. Gendron , O. Benrezzak , B.W. Krugh , Q. Kong , G.A. Weisman and A.R. Beaudoin , Purine Signaling and Potential New Therapeutic Approach: Possible Outcomes of NTPDase Inhibition, Current Drug Targets 2002; 3 (3) . https://dx.doi.org/10.2174/1389450023347713
DOI https://dx.doi.org/10.2174/1389450023347713 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small Molecule Integrin Antagonists in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Exosomal MicroRNAs in Tumoral U87 MG Versus Normal Astrocyte Cells
MicroRNA Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Recent Advances in the Chemistry and Synthesis of Thienopyrazine, Pyrrolopyrazine and Furopyrazine Derivatives
Current Organic Chemistry Poly(ethylene glycol)-polypeptide Copolymer Micelles for Therapeutic Agent Delivery
Current Pharmaceutical Biotechnology Synthesis, Computational Study, and Evaluation of In Vitro Antimicrobial, Antibiofilm, and Anticancer Activities of New Sulfanyl Aminonaphthoquinone Derivatives
Letters in Drug Design & Discovery Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Novel Strategies to Improve DNA Vaccine Immunogenicity
Current Gene Therapy Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Peptide Nucleic Acid Conjugates: Synthesis, Properties and Applications
Current Topics in Medicinal Chemistry Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status
Current Pharmaceutical Design Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) Considering Autotaxin Inhibitors in Terms of 2D-QSAR and 3D-Mapping- Review and Evaluation
Current Medicinal Chemistry Ghetto Poverty and Pollution in Egypt: A Deadly Threat for Western Countries Caused by New and Infectious Mutants. A Cultural, Social and Microbiological Synopsis
Inflammation & Allergy - Drug Targets (Discontinued) Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine